Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-13 2:59 pm Sale | 13G | Kinnate Biopharma Inc. KNTE | Vida Ventures LLC | 0 0.000% | -2,207,772 (Position Closed) | View |
| 2024-05-03 5:57 pm Purchase | 13D | KYVERNA THERAPEUTICS INC KYTX | Vida Ventures LLC | 4,777,060 11.100% | 4,777,060 (New Position) | View |
| 2023-02-13 4:21 pm Sale | 13G | Kinnate Biopharma Inc. KNTE | Vida Ventures LLC | 2,207,772 5.000% | -539,661 (-19.64%) | View |
| 2023-02-10 4:16 pm Sale | 13G | Praxis Precision Medicines Inc. PRAX | Vida Ventures LLC | 1,469,665 3.100% | -1,469,664 (-50.00%) | View |
| 2022-02-10 5:17 pm Purchase | 13G | Kinnate Biopharma Inc. KNTE | Vida Ventures LLC | 2,747,433 6.300% | 359 (+0.01%) | View |
| 2021-02-12 5:49 pm Purchase | 13G | Praxis Precision Medicines Inc. PRAX | Vida Ventures LLC | 2,939,329 7.700% | 2,939,329 (New Position) | View |
| 2021-02-12 5:40 pm Purchase | 13G | Kinnate Biopharma Inc. KNTE | Vida Ventures LLC | 2,747,074 6.300% | 2,747,074 (New Position) | View |